(2,3,3,4,5,5,5,5',5',5'-2H10)Leucine
Modify Date: 2024-01-03 13:08:35
(2,3,3,4,5,5,5,5',5',5'-2H10)Leucine structure
|
Common Name | (2,3,3,4,5,5,5,5',5',5'-2H10)Leucine | ||
|---|---|---|---|---|
| CAS Number | 271247-12-2 | Molecular Weight | 141.23 | |
| Density | 1.0±0.1 g/cm3 | Boiling Point | 225.8±23.0 °C at 760 mmHg | |
| Molecular Formula | C6H3D10NO2 | Melting Point | >300ºC(lit.) | |
| MSDS | N/A | Flash Point | 90.3±22.6 °C | |
Use of (2,3,3,4,5,5,5,5',5',5'-2H10)LeucineD-Leucine-d10 is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro[1]. |
| Name | d-leucine-d10 |
|---|---|
| Synonym | More Synonyms |
| Description | D-Leucine-d10 is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro[1]. |
|---|---|
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
| References |
| Density | 1.0±0.1 g/cm3 |
|---|---|
| Boiling Point | 225.8±23.0 °C at 760 mmHg |
| Melting Point | >300ºC(lit.) |
| Molecular Formula | C6H3D10NO2 |
| Molecular Weight | 141.23 |
| Flash Point | 90.3±22.6 °C |
| Exact Mass | 141.157394 |
| PSA | 63.32000 |
| LogP | 0.73 |
| Vapour Pressure | 0.0±0.9 mmHg at 25°C |
| Index of Refraction | 1.463 |
| WGK Germany | 3 |
|---|
| Leucine-2,3,3,4,5,5,5,5',5',5'-d |
| (2,3,3,4,5,5,5,5',5',5'-H)Leucine |